Quince Therapeutics (NASDAQ:QNCX – Free Report) had its target price cut by D. Boral Capital from $12.00 to $4.00 in a ...

D. Boral Capital reaffirmed their buy rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $15.00 ...

VIRGINIA BEACH, VA / ACCESS Newswire / March 25, 2025 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) ("Inspire" or the ...

Fintel reports that on March 10, 2025, D. Boral Capital initiated coverage of Pulmonx (NasdaqGS:LUNG) with a Buy recommendation. Analyst Price Forecast Suggests 65.05% Upside As of March 4, 2025, the ...

(NYSE:ANVS) experienced a change in stock rating as D. Boral (OTC:BOALY) Capital downgraded the company from Buy to Hold. The stock, currently trading at $2.94, has seen its value decline by over ...

D. Boral Capital initiated coverage of Plus Therapeutics (PSTV) with a Buy rating and $9 price target Plus is advancing a unique approach in ...

Australian construction materials company Boral has debuted a proprietary crumbed rubber asphalt bitumen that replaces common ...

Boral Capital LLC acted as underwriters for the Offering (the "Underwriters"). Dykema Gossett PLLC is acting as securities counsel to the Company, and Sichenzia Ross Ferrance Carmel LLP is acting ...

D. Boral Capital analyst Jesse Sobelson reiterated a Buy rating on the shares of MicroVision Inc (NASDAQ:MVIS) with a price ...

D. Boral Capital initiated coverage of Pulmonx (LUNG) with a Buy rating and $17 price target The firm says Pulmonx is a commercial-stage ...

Boral Capital initiated coverage of Aduro Clean ... Citadel Advisors holds 22K shares representing 0.07% ownership of the company. One Wealth Advisors holds 22K shares representing 0.07% ownership ...